This page provides Regulatory news filings submitted by issuers listed on the BSX. Please note the BSX is not responsible for the content, accuracy or completeness of announcements filed by issuers and disclaims all liability for any loss arising from reliance on information contained within issuer announcements.

Jazz Pharmaceuticals to Report 2018 Second Quarter Financial Results on August 7, 2018

25 July 2018

Hamilton, Bermuda – July 25 2018 – In a filing with the Bermuda Stock Exchange (“BSX”), Jazz Pharmaceuticals plc (Nasdaq: JAZZ) whose Secured Loan Notes are listed on the BSX announced that it will report its 2018 second quarter financial results on Tuesday, August 7, 2018.  The full filing stated:

DUBLIN,July24,2018/PRNewswire/--JazzPharmaceuticalsplc(Nasdaq:JAZZ)todayannouncedthatitwill reportits2018second quarterfinancialresults onTuesday,August7, 2018,afterthe closeof thefinancial markets.Company managementwill host alive audiowebcastimmediatelyfollowingtheannouncementat4:30p.m.EDT/9:30p.m.ISTtodiscusssecondquarter2018financialresultsandprovideabusinessandfinancialupdate.

 

Interestedpartiesmay accessthe liveaudiowebcast viatheInvestorssectionof theJazzPharmaceuticalswebsiteathttp://www.jazzpharmaceuticals.com.Pleaseconnecttothewebsitepriorto the start of theconference call to ensure adequatetime for any software downloadsthatmay benecessary tolisten tothe webcast.A replayof thewebcastwill bearchived onthe websitefor at leastone week.

 

Audiowebcast/conferencecall:

U.S. Dial-In Number:+1855 353 7924InternationalDial-InNumber:+15033436056Passcode:4989706

 

Areplayof theconferencecall willbeavailable throughAugust 14,2018and accessiblethroughoneofthefollowingtelephonenumbers,usingthepasscodebelow:

 

ReplayU.S. Dial-InNumber:+1855 8592056

ReplayInternationalDial-InNumber:+14045373406

Passcode:4989706

 

AboutJazzPharmaceuticals

JazzPharmaceuticalsplc(Nasdaq:JAZZ)isaninternationalbiopharmaceuticalcompanyfocusedonimprovingpatients’livesbyidentifying,developingandcommercializingmeaningfulproductsthataddressunmetmedicalneeds.The companyhasadiverseportfolioof productsandproductcandidateswith afocusinthe areasofsleep andhematology/oncology.Inthese areas,JazzPharmaceuticalsmarketsXyrem®(sodiumoxybate)oralsolution,Erwinaze®(asparaginaseErwiniachrysanthemi),Defitelio®(defibrotidesodium)andVyxeos®(daunorubicinandcytarabine)liposomeforinjectionintheU.S.andmarketsErwinase®andDefitelio®(defibrotide)incountriesoutsidetheU.S.Forcountry-specificproductinformation,pleasevisit http://www.jazzpharmaceuticals.com/products.Formoreinformation,pleasevisit http://www.jazzpharmaceuticals.com/andfollowusonTwitterat@JazzPharma.

 

 

 


JazzPharmaceuticalsContacts:

Investors:

KatheeLittrell

VicePresident,InvestorRelationsIreland,+3531 6347887

U.S., +1 650 496 2717

 

Media:

JacquelineKirby

VicePresident,CorporateAffairs&GovernmentRelationsIreland,+3531 6972141

U.S., +1 215 867 4910

MIAX Logo

Disclaimer and Privacy Policy    Complaints Policy

Copyright © 2024 by Bermuda Stock Exchange. All rights reserved!

Questions or requests for information can be emailed to  info@bsx.com